<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04064905</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1893-P101</org_study_id>
    <secondary_id>BARDA HHS010020160029C</secondary_id>
    <nct_id>NCT04064905</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults</brief_title>
  <official_title>A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will evaluate the safety, tolerability and reactogenicity of mRNA-1893
      Zika vaccines in flavivirus seronegative and flavivirus seropositive participants
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Observer blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and grade of each solicited local and systemic reactogenicity adverse event (AE)</measure>
    <time_frame>7-day follow-up period after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and grade of any unsolicited AEs</measure>
    <time_frame>28-day follow-up period after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of any medically attended adverse event (MAAE), serious adverse event (SAE), and adverse event of special interest (AESI)</measure>
    <time_frame>Day 1 to the end of study (EOS) Visit at Month 13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer (GMT) of serum neutralizing antibodies (nAb) against zika virus (ZIKV) as measured by Plaque Reduction Neutralization Test (PRNT)</measure>
    <time_frame>Day 1, Day 29, Day 57, Month 7, and Month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of nAb in initially seronegative participants against ZIKV as measured by PRNT</measure>
    <time_frame>Day 1, Day 29, Day 57, Month 7, and Month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of nAb in initially seropositive participants against ZIKV as measured by PRNT</measure>
    <time_frame>Day 1, Day 29, Day 57, Month 7, and Month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who seroconverted</measure>
    <time_frame>Day 1 (baseline) to Day 29, from Day 1 to Day 57, from Day 1 to Month 7, and from Day 1 to Month 13</time_frame>
    <description>A seroconversion is defined as a change of PRNT from below the LOQ to a PRNT equal to or above 1:10, or a multiplication by at least 4 in subjects with pre-existing PRNT titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of initially seronegative participants with a seroresponse as measured by PRNT</measure>
    <time_frame>Day 29, Day 57, Month 7, and Month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of initially seropositive participants with a 2-fold or 4-fold increase in nAb titers as compared with baseline as measured by PRNT</measure>
    <time_frame>Day 29, Day 57, Month 7, and Month 13</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Zika Virus</condition>
  <arm_group>
    <arm_group_label>mRNA-1893</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1893</intervention_name>
    <description>Zika vaccine</description>
    <arm_group_label>mRNA-1893</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agrees to comply with the study procedures and provides written informed consent

          -  18 to 49 years of age

          -  In the opinion of the investigator, can and will comply with the requirements of the
             protocol (e.g., complete diary cards, return for follow-up visits, be available for
             safety telephone calls).

          -  Is in good general health, as determined by medical history, clinical laboratory
             assessments, vital sign measurements, and physical examination at screening.

          -  Negative urine pregnancy test at the Screening visit and at the day of each
             vaccination for females of childbearing potential.

          -  Male participants must agree to practice adequate contraception from the time of the
             first vaccination and through 3 months following the last vaccination.

          -  For flavivirus-seropositive group, has positive flavivirus test results (including
             dengue, West Nile, and Zika) as determined by ELISA or other commercially available
             serological assay.

          -  For flavivirus-seronegative group, has negative flavivirus test results (including
             dengue, West Nile, and Zika) as determined by ELISA or other commercially available
             serological assay.

        Exclusion Criteria:

          -  Has any acute or chronic, Clinically Significant disease in the opinion of the
             investigator.

          -  Has received a vaccine for dengue, Japanese encephalitis, tick-borne encephalitis,
             West Nile, Yellow Fever, or Zika.

          -  Has a neurologic disorder

          -  Has a body mass index that is ≤ 18 or ≥ 35 kg/m2.

          -  Has elevated liver function tests

          -  Has clinical laboratory test results (hematology, serum chemistry, or coagulation)
             with a toxicity score of Grade ≥ 1 at Screening.

          -  Has a bleeding disorder that would contraindicate IM injections or phlebotomy.

          -  Reports a diagnosis of congenital or acquired immunodeficiency (including HIV
             infection), or autoimmune disease.

          -  Has a history of hypersensitivity or severe reactions to previous vaccinations or any
             component of the study vaccine.

          -  Has a history of idiopathic urticaria.

          -  Reports a previous diagnosis of hematologic malignancy or pre-malignancy or a
             diagnosis of any other malignancy within the previous 10 years (excluding nonmelanoma
             skin cancer).

          -  Has a medical, psychiatric, or occupational condition that, in the opinion of the
             investigator, might pose an additional risk to the participant due to participation in
             the study or would interfere with the evaluation of the study vaccines or the
             interpretation of study results.

          -  Is acutely ill or febrile on the day of screening (Day 0) or randomization (Day 1).

          -  Has a history of inflammatory arthritis.

          -  Has a history of febrile disease with arthritis or arthralgia within 2 weeks of
             administration of any study vaccine.

          -  Has received an investigational or nonregistered product (drug or vaccine) within 30
             days before the first dose of study vaccine or has plans for administration during the
             study period.

          -  Has received or is scheduled to receive an inactivated vaccine within the period from
             14 days before, or through 14 days after, administration of any study vaccination.

          -  Has received or is scheduled to receive a live virus vaccine administered within the
             period from 28 days before, or through 28 days after, any dose of study vaccine.

          -  Has received chronic administration (defined as &gt; 14 total days) of immunosuppressants
             or other immune-modifying drugs within 6 months before the first study vaccine dose.

          -  Has received immunoglobulins and/or blood products within the 3 months before the
             first study vaccine dose or has plans for administration during the study period.

          -  Has a positive test result at the Screening Visit for hepatitis B surface antigen,
             hepatitis C virus antibody, or HIV type 1 or 2 antibodies.

          -  Has donated &gt; 450 mL of whole blood or blood products within 30 days of enrollment or
             plans to do so during the study period.

          -  Is an immediate family member or household member of study personnel.

          -  Previously participated in an investigational study involving LNPs.

          -  Has a positive urine drug screen result at Screening for any of the following
             nonprescription drugs of abuse: amphetamines, benzodiazepines, cocaine, methadone,
             opiates, and phencyclidine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Meridan Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine - CAIMED Center</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRNA-1893</keyword>
  <keyword>zika vaccine</keyword>
  <keyword>Moderna</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zika Virus Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

